Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Alimera’s Iluvien Fails to Win Backing From U.K. Cost Agency

Alimera Sciences Inc. failed to win the backing of the U.K.’s health-cost agency for its treatment for the leading cause of blindness associated with diabetes.

Alimera “underestimated the incremental cost-effectiveness ratio” of Iluvien, an implant that releases a drug that can limit vision loss or improve vision for patients with chronic diabetic macular edema, the National Institute for Health and Clinical Excellence said in a statement today.

“The independent Appraisal Committee is aware that chronic diabetic macular edema can have a significant effect on the physical and emotional wellbeing of people affected,” NICE said. “Unfortunately in this case, the committee agreed that the evidence provided could not support a positive recommendation.”

The existing option for patients is to receive laser therapy. Roche Holding AG is currently seeking U.S. approval for a similar drug, Lucentis, to treat diabetic macular edema. The Food and Drug Association has twice rejected Iluvien, most recently in November.

The draft appraisal is open to public comment, and NICE will probably issue final guidance in November, it said.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.